Glaucoma Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape

Glaucoma Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape

Summary

This reports provides a data-driven overview of the current and future competitive landscape in Glaucoma therapeutics.

Synopsis

• In 2022, there will be more than 18 million total prevalent cases of glaucoma across 16 pharmaceutical markets.
• There are 10 marketed leading drugs for the treatment of glaucoma, Prostaglandin analogues are generally used as a first-line treatment.
• The R&D activity in glaucoma is steady, with five products in pre-registration stage and 18 products in Phase III development.
• Commercial sponsors dominate clinical trial development in glaucoma, with the US emerging as the key country for conducting Phase III trials in glaucoma.
• During the past 12 months, there have been 10 mergers & acquisitions and five strategic alliances involving companies developing glaucoma assets.
• A trend of strong generic competition is likely to be continued in the glaucoma market throughout the forecast period.

Scope

GlobalData’s Glaucoma Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.

Components of the report include -

• Disease Landscape
• Disease Overview
• Epidemiology Overview
• Treatment Overview
• Marketed Products Assessment
• Breakdown by Mechanism of Action, Molecule Type, Route of Administration
• Product Profiles with Sales Forecast
• Pricing and Reimbursement Assessment
• Retail or Manufacturer Price of Products
• Time to Pricing and Time to Reimbursement
• Pipeline Assessment
• Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
• Product Profiles with Sales Forecast
• Late-to-mid-stage Pipeline Drugs
• Phase Transition Success Rate and Likelihood of Approval
• Clinical Trials Assessment
• Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
• Enrolment Analytics, Site Analytics, Feasibility Analysis
• Deals Landscape
• Mergers, Acquisitions, and Strategic Alliances by Region
• Overview of Recent Deals
• Commercial Assessment
• Key Market Players
• Future Market Catalysts

Reasons to Buy

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the Glaucoma market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global Glaucoma market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.